Stem Cells
Therapies
Stem Cells Therapies
The purpose of banking stem cells is to apply them in the therapy. For the first time cord blood was used in 1988 and since then according to publicly available statistics it has been used over 85 000 times worldwide (including statistics of China).
FamiCord Group stores over 1,000,000 samples of cells of different types and has supplied stem cells for application in clinic for more than 7000 patients. We supply stem cells for standard transplantations (cord blood , bone marrow and mobilized peripheral blood) and cellular therapies. On top of that we provide cell based products in GMP standard for clinical trials.
Stem cells manufactured in our premises helped patients with various diseases and therapeutic areas, including haematological, neurological, ophthalmological, orthopaedical, dermatological disorders.
Check the full list of patients who received stem cell therapy derived from FamiCord labs.
List last update: 06.2026
List of patients who received stem cells from FamiCord Group laboratories
| Lp. | Source | Source type | Diagnosis | Medical field | Year of application | Therapy | Country | Age of recipient |
|---|---|---|---|---|---|---|---|---|
| 501 | Apheresis | Allogeneic | Plasma Cell Leukemia | Hematology | 2026 | Standard Therapy | Germany | 62 |
| 502 | Apheresis | Allogeneic | Hodgkin’s Disease | Hematology | 2026 | Standard Therapy | Italy | 34 |
| 503 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | France | 20 |
| 504 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 40 |
| 505 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Spain | 51 |
| 506 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 58 |
| 507 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2026 | Standard Therapy | Ukraine | 45 |
| 508 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Ukraine | 41 |
| 509 | Apheresis | Allogeneic | Hodgkin’s Disease | Hematology | 2026 | Standard Therapy | Poland | 44 |
| 510 | Apheresis | Allogeneic | Multiple Myeloma | Hematology | 2026 | Standard Therapy | USA | 47 |
| 511 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Colombia | 57 |
| 512 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2026 | Standard Therapy | Australia | 72 |
| 513 | Apheresis | Allogeneic | EBV-positive nodal T- and NK-cell lymphoma | Hematology | 2026 | Standard Therapy | Poland | 68 |
| 514 | Apheresis | Allogeneic | Acute Myeloid Leukemia, Myelodysplasia-Related | Hematology | 2026 | Standard Therapy | Russia Federation | 48 |
| 515 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Finland | 69 |
| 516 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 67 |
| 517 | Apheresis | Allogeneic | Large Cell Anaplastic Lyphoma ALK | Hematology | 2026 | Standard Therapy | Serbia | 13 |
| 518 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 74 |
| 519 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2026 | Standard Therapy | Lithuania | 64 |
| 520 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Germany | 67 |
| 521 | Apheresis | Allogeneic | Acute Undifferentiated Leukemia | Hematology | 2026 | Standard Therapy | USA | 16 |
| 522 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Czechia | 53 |
| 523 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 68 |
| 524 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | India | 18 |
| 525 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 50 |
| 526 | Apheresis | Allogeneic | Chronic myelomonocytic leukemia | Hematology | 2026 | Standard Therapy | Lithuania | 66 |
| 527 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 51 |
| 528 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 41 |
| 529 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 72 |
| 530 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 70 |
| 531 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 61 |
| 532 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Lithuania | 62 |
| 533 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Australia | 62 |
| 534 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2026 | Standard Therapy | Spain | 61 |
| 535 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 58 |
| 536 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | India | 2 |
| 537 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2026 | Standard Therapy | Germany | 21 |
| 538 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 63 |
| 539 | Apheresis | Autologous | Diffuse Large B-cell Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 71 |
| 540 | Apheresis | Allogeneic | Acute Myeloid Leukemia | Hematology | 2026 | Standard Therapy | Germany | 61 |
| 541 | Apheresis | Autologous | Mantle Cell Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 65 |
| 542 | Apheresis | Autologous | T-Cell Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 64 |
| 543 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 70 |
| 544 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 59 |
| 545 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 66 |
| 546 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 61 |
| 547 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 53 |
| 548 | Apheresis | Allogeneic | Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | France | 26 |
| 549 | Apheresis | Allogeneic | Inherited Metabolic Disorder | Hematology | 2026 | Standard Therapy | France | 50 |
| 550 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 70 |
| 551 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | France | 70 |
| 552 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Argentina | 30 |
| 553 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 74 |
| 554 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 61 |
| 555 | Apheresis | Allogeneic | Hyper IgE Syndrome | Hematology | 2026 | Standard Therapy | Australia | 11 |
| 556 | Apheresis | Allogeneic | AML FLT3+ | Hematology | 2026 | Standard Therapy | Croatia | 61 |
| 557 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 61 |
| 558 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Australia | 58 |
| 559 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Iran | 3 |
| 560 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2026 | Standard Therapy | USA | 59 |
| 561 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Germany | 58 |
| 562 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | United Kingdom | 10 |
| 563 | Apheresis | Allogeneic | Lymphoma – Peripheral T cell | Hematology | 2026 | Standard Therapy | United Kingdom | 53 |
| 564 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | Italy | 48 |
| 565 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Spain | 13 |
| 566 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Italy | 58 |
| 567 | Apheresis | Allogeneic | Myelofibrosis Myeloid Metaplasia | Hematology | 2026 | Standard Therapy | USA | 69 |
| 568 | Apheresis | Allogeneic | Peripheral T Cell Lymphoma With Haemophagocytic Lymphohistiocytosis | Hematology | 2026 | Standard Therapy | United Kingdom | 52 |
| 569 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Germany | 62 |
| 570 | Apheresis | Allogeneic | T-Cell Prolymphocytic Leukemia | Hematology | 2026 | Standard Therapy | Italy | 72 |
| 571 | Apheresis | Allogeneic | Myelodysplastic Disorder | Hematology | 2026 | Standard Therapy | Russian Federation | 51 |
| 572 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 64 |
| 573 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 62 |
| 574 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | USA | 49 |
| 575 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2026 | Standard Therapy | USA | 75 |
| 576 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 68 |
| 577 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 58 |
| 578 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Spain | 52 |
| 579 | Apheresis | Allogeneic | Myelodysplastic Syndrome | Hematology | 2026 | Standard Therapy | USA | 69 |
| 580 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 20 |
| 581 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 65 |
| 582 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Belgium | 34 |
| 583 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 67 |
| 584 | Apheresis | Allogeneic | Myelofibrosis | Hematology | 2026 | Standard Therapy | Poland | 69 |
| 585 | Apheresis | Allogeneic | T-Cell Acute lymphoblastic leukemia | Hematology | 2026 | Standard Therapy | Netherlands | 21 |
| 586 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 70 |
| 587 | Apheresis | Allogeneic | Chronic Myelomonocytic Leukemia | Hematology | 2026 | Standard Therapy | USA | 68 |
| 588 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Poland | 16 |
| 589 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | Germany | 65 |
| 590 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 61 |
| 591 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 65 |
| 592 | Apheresis | Autologous | Central Nervous System Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 65 |
| 593 | Apheresis | Autologous | Diffuse Large B-cell Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 45 |
| 594 | Apheresis | Autologous | Multiple Myeloma | Hematology | 2026 | Standard Therapy | Germany | 61 |
| 595 | Apheresis | Allogeneic | B-cell Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Germany | 21 |
| 596 | Apheresis | Autologous | Mantle Cell Lymphoma | Hematology | 2026 | Standard Therapy | Germany | 65 |
| 597 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 68 |
| 598 | Apheresis | Allogeneic | Acute Lymphoblastic Leukemia | Hematology | 2026 | Standard Therapy | Ukraine | 5 |
| 599 | Apheresis | Allogeneic | Non-Hodgkin Lymphoma | Hematology | 2026 | Standard Therapy | Hungary | 57 |
| 600 | Apheresis | Allogeneic | Acute Myelogenous Leukemia | Hematology | 2026 | Standard Therapy | USA | 30 |